Welcome to this week’s Dental AI Weekly, honest analysis of where dental AI is going, from someone building in it.
Some dental technology is hard to judge because a practice cannot easily use it.
A test may not be covered. A three-dimensional scan may depend on a specialist workflow. A software evaluation may start with a sales call before anyone on the team can use the product.
Three developments this week removed one of those barriers. United Concordia and PDS Health began a funded saliva-screening pilot. Pearl launched its 3D imaging AI for general dentists. OraCore opened free self-service trials for Scribe Solo and Scribe Team.
Easier access does not prove that a tool improves care or earns a permanent place in the practice. It does make the next question easier to answer: what happens when real patients and dental teams use it?
WHAT HAPPENED THIS WEEK
01 – SALIVA SCREENING
United Concordia and PDS Health began an 18-month pilot of chairside saliva screening in Southern California.
The September 3 announcement describes a pilot at nearly 125 PDS Health practices involving approximately 1,500 to 2,000 eligible United Concordia members who have gum disease or are at risk and are undergoing treatment. The screening measures active matrix metalloproteinase-8, or aMMP-8, a biomarker associated with collagen breakdown and active periodontal tissue destruction. United Concordia will fund the screening at no cost to eligible members diagnosed with gum disease.
Follow-up screenings will track the biomarker during treatment, while patient surveys will track brushing, flossing, and other home care. The study will examine whether the screening helps patients manage gum disease and follow treatment, and whether the results can inform patient education or future benefit coverage.
What this means: The saliva pilot is testing something every dentist recognizes: whether clearer evidence changes what a patient does after leaving the chair. The pilot has not answered that question. Payer funding lets the test be evaluated during routine periodontal care without adding a charge for eligible members diagnosed with gum disease.
02 – CBCT
Pearl launched its FDA-cleared 3D imaging AI as a commercial product for general dentists.
Pearl launched Second Opinion 3D in the United States and Canada on September 3. The product uses AI-enabled segmentation to identify and display anatomy in cone-beam computed tomography, or CBCT, scans. CBCT is a three-dimensional dental X-ray.
Pearl says the product is designed for chairside use through the same Second Opinion interface used for 2D imaging. Dentists can request a licensed oral and maxillofacial radiologist’s report in the interface, and the product can turn 3D findings into insurance claim-ready documentation. The underlying AI received FDA 510(k) clearance in 2025. This week’s news is the commercial launch, not a new clearance. Pearl says pathology detection is available in Canada and is pending regulatory approval in additional markets.
What this means: Pearl is trying to close the gap between owning a CBCT unit and using its scans during an ordinary general-practice appointment. Image segmentation, chairside explanation, specialist review, and claim documentation now sit in one workflow.
03 – ORACORE UPDATE
OraCore opened free 14-day self-service trials for Scribe Solo and Scribe Team.
Both products can now be tried without a sales call or credit card. Scribe Solo is built for one provider and produces a clinical-note draft with a diarized transcript for review and manual export. Scribe Team supports unlimited providers at one location. A captured appointment can produce six drafts for review: a clinical note, visit summary, Checkout handoff, insurance narrative with suggested attachments, patient follow-up email, and referral letter.
Solo and Team do not connect to a practice management system or automatically write to the chart, send messages, submit claims, or schedule care. Scribe Pro still requires a demo and is not part of this trial announcement.
What this means: A practice can now use Solo or Team in its own workflow, inspect the drafts, and decide whether the product removes enough work to keep.
“The saliva pilot is testing something every dentist recognizes: whether clearer evidence changes what a patient does after leaving the chair.”
THE BIGGER SIGNAL
All three stories are about access, but each removes a different gate.
The saliva pilot removes the screening cost for eligible members diagnosed with gum disease. Pearl is packaging a specialist-heavy imaging workflow for general practice. OraCore is letting practices evaluate two Scribe products before entering a paid plan.
That matters because adoption claims are easy to make when the people evaluating a tool are self-selected, well trained, or willing to absorb extra cost. Wider access creates a better test. Does a number change patient behavior? Does 3D segmentation help a general dentist use a scan more confidently? Does a scribe save time once the novelty wears off?
Lower friction is not proof. It gives each technology a fairer test in a real practice.
BY THE NUMBERS
Nearly 125
PDS Health practices in Southern California are expected to participate in the saliva-screening pilot.
What it signals: The project will test the screening across many practice teams and patient conversations, but it remains a pilot. The useful result will be whether participating patients change their home care or treatment follow-through, not how many offices offer the test.
Source: United Concordia Dental and PDS Health, September 3, 2026.
READER Q&A
“When a patient cannot see or feel their gum disease, what evidence actually changes their mind about treatment?”
Practice question selected for Issue 029
BH: No single image, number, or test changes every patient’s mind. Trust does.
AI is not the doctor, and it cannot diagnose the patient or replace the treating clinician’s judgment. It can support the clinician by helping organize and explain the evidence behind an assessment. The dentist remains responsible for the diagnosis and treatment recommendation. Then the hygienist, assistant, and front desk carry that understanding forward through each handoff.
To the patient, those handoffs can feel like a second or third perspective, even though they are not separate diagnoses. When the whole team uses the same language, supports the treating clinician’s recommendation, and can explain what happens next without contradicting one another, I believe it builds trust. The evidence helps make the condition visible. A coordinated team helps the patient understand and trust what they are hearing. In my experience, that trust is what changes minds.
FROM THE ORACORE BLOG THIS WEEK
Patient Trust | 4 min
Dental AI, Prevention, and Patient Trust
AI should make prevention easier to understand, not scarier. This article looks at how the dentist, hygiene team, checkout team, and follow-up workflow can use clear language while keeping clinical judgment with the treating clinician.
Evaluation | 4 min
Choosing a Dental AI Scribe: 7 Evaluation Criteria
A free trial is useful only if the practice knows what to test. Use these seven criteria to judge capture quality, dental workflow fit, review control, PMS scope, and what happens after the note.
Try OraCore Scribe in your own practice for 14 days. Scribe Solo and Scribe Team are now available through self-service signup with no credit card required.
That’s the week. Reply with what you’re seeing in your own practice. I read every one.
Brad Hutchison
CEO, OraCore AI
Dental AI Weekly drops every Monday. pulse@oracorenews.com | OraCore AI, Denver CO